Intrahepatic transit time predicts liver fibrosis in patients with chronic hepatitis b: Quantitative assessment with contrast-enhanced ultrasonography

Ultrasound in Medicine and Biology

Volumn 36, Issue 7, 2010, Pages 1066-1075

  Li, Na ^a   Ding, Hong ^a   Fan, Peili ^a   Lin, Xiyuan ^a   Xu, Chen ^a   Wang, Wenping ^a   Xu, Zhizhang ^a   Wang, Jiyao ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Chronic hepatitis; Cirrhosis; Contrast enhanced ultrasonography; Intrahepatic transit time; Liver fibrosis; Quantitative assessment

Indexed keywords

CHRONIC HEPATITIS; CONTRAST-ENHANCED ULTRASONOGRAPHY; LIVER FIBROSIS; QUANTITATIVE ASSESSMENTS; TRANSIT TIME;

ULTRASONIC IMAGING; ULTRASONOGRAPHY;

LIVER;

SONOVUE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; GASTROINTESTINAL TRANSIT; HEMODYNAMICS; HEPATIC ARTERY; HEPATIC VEIN; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTRAHEPATIC TRANSIT TIME; LIVER BIOPSY; LIVER BLOOD VESSEL; LIVER CIRCULATION; LIVER FIBROSIS; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME ECHOGRAPHY; RELIABILITY; SCHEUER SCORING SYSTEM; SCORING SYSTEM;

ADULT; ALGORITHMS; COMPUTER SIMULATION; CONTRAST MEDIA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER CIRRHOSIS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; PHOSPHOLIPIDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SULFUR HEXAFLUORIDE;

EID: 77953880496     PISSN: 03015629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ultrasmedbio.2010.04.012     Document Type: Article

References (53)

1. Abbattista T., Ridolfi F., Ciabattoni E., Marini F., Bendia E., Brunelli E., Busilacchi P. Diagnosis of liver cirrhosis by transit-time analysis at contrast-enhanced ultrasonography. Radiol Med 2008, 113:860-874.
2. Albrecht T., Blomley M.J.K., Cosgrove D.O., Taylor-Robinson S.D., Jayaram V., Eckersley R., Urbank A., Butler-Barnes J., Patel N. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999, 353:1579-1583.
3. Albrecht T., Urbank A., Mahler M., Bauer A., Dore C.J., Blomley M.J.K., Cosgrove D.O., Schlief R. Prolongation and optimization of Doppler enhancement with a microbubble US contrast agent by using continuous infusion: Preliminary experience. 82nd Annual Meeting of the Radiological Society of North America 1996, Radiological Society of North America, Chicago, IL, 339-347.
4. Bang N., Nielsen M.B., Rasmussen A.N., Osterhammel P.A., Pedersen J.F. Hepatic vein transit time of an ultrasound contrast agent: simplified procedure using pulse inversion imaging. Br J Radiol 2001, 74:752-755.
5. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
6. Bleuzen A., Tranquart F. Incidental liver lesions: Diagnostic value of cadence contrast pulse sequencing (CPS) and SonoVue. Eur Radiol 2004, 14:P53-P62.
7. Blomley M.J., Cosgrove D.O., Jayaram V., Eckersley R., Albrecht T., DeSouza N.M. Quantitation of enhanced transrectal ultrasound of the prostate: Work in progress using the echo-enhancing agent Br1. Radiology 1997, 205:598.
8. Cadranel J.F., Rufat P., Degos F. Practices of liver biopsy in France: Results of a prospective nationwide survey. Hepatology 2000, 32:477-481.
9. TM contrast pulse sequencing technology (CPS) and SonoVue (BR1). Eur Radiol 2004, 14:P1-P3.
10. Eyding J., Krogias C., Wilkening W., Meves S., Ermert H., Postert T. Parameters of cerebral perfusion in phase-inversion harmonic imaging (PIHI) ultrasound examinations. Ultrasound Med Biol 2003, 29:1379-1385.
11. Fabris C., Smirne C., Toniutto P., Colletta C., Rapetti R., Minisini R., Falleti E., Leutner M., Pirisi M. Usefulness of six non-proprietary indirect markers of liver fibrosis in patients with chronic hepatitis C. Clin Chem Lab Med 2008, 46:253-259.
12. Forns X., Ampurdanes S., Llovet J.M., Aponte J., Quinto L., Martinez-Bauer E., Bruguera M., Sanchez-Tapias J.M., Rodes J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36:986-992.
13. Goyal N., Jain N., Rachapalli V., Cochlin D.L., Robinson M. Non-invasive evaluation of liver cirrhosis using ultrasound. Clin Radiol 2009, 64:1056-1066.
14. Hirota M., Kaneko T., Sugimoto H., Kure S., Inoue S., Takeda S., Nakao A. Intrahepatic circulatory time analysis of an ultrasound contrast agent in liver cirrhosis. Liver Int 2005, 25:337-342.
15. Hohmann J., Müller C., Oldenburg A., Skrok J., Frericks B.B., Wolf K.J., Albrecht T. Hepatic transit time analysis using contrast-enhanced ultrasound with BR1: A prospective study comparing patients with liver metastases from colorectal cancer with healthy volunteers. Ultrasound Med Biol 2009, 35:1427-1435.
16. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001, 357:1069-1075. MULTIVIRC Group.
17. Kleber G., Steudel N., Behrmann C., Zipprich A., Hubner G., Lotterer E., Fleig W.E. Hepatic arterial flow volume and reserve in patients with cirrhosis: Use of intra-arterial Doppler and adenosine infusion. Gastroenterology 1999, 116:906-914.
18. Koda M., Matunaga Y., Kawakami M., Kishimoto Y., Suou T., Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007, 45:297-306.
19. Krogias C., Postert T., Meves S., Wilkening W., Przuntek H., Eyding J. Semiquantitative analysis of ultrasonic cerebral perfusion imaging. Ultrasound Med Biol 2005, 31:1007-1012.
20. Lauer G.M., Walker B.D. Medical progress: Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
21. Lim A.K., Patel N., Eckersley R.J., Goldin R.D., Thomas H.C., Cosgrove D.O., Taylor-Robinson S.D., Blomley M.J. Hepatic vein transit time of SonoVue: A comparative study with Levovist. Radiology 2006, 240:130-135.
22. Lim A.K.P., Patel N., Eckersley R.J., Taylor-Robinson S.D., Cosgrove D.O., Blomley M.J.K. Evidence for spleen-specific uptake of a microbubble contrast agent: A quantitative study in healthy volunteers. Radiology 2004, 231:785-788.
23. Lok A.S., McMahon B.J. Chronic hepatitis B: Update of recommendations. Hepatology 2004, 39:857-861.
24. Lucidarme O., Kono Y., Corbeil J., Choi S.H., Golmard J.L., Varner J., Mattrey R.F. Angiogenesis: Noninvasive quantitative assessment with contrast-enhanced functional US in murine model. Radiology 2006, 239:730-739.
25. Lucidarme O., Kono Y., Corbeil J., Choi S.H., Mattrey R.F. Validation of ultrasound contrast destruction imaging for flow quantification. Ultrasound Med Biol 2003, 29:1697-1704.
26. Metoki R., Moriyasu F., Kamiyama N., Sugimoto K., Iijima H., Xu H.X., Aoki T., Miyata Y., Yamamoto K., Kudo K., Shimizu M., Yamada M. Quantification of hepatic parenchymal blood flow by contrast ultrasonography with flash-replenishment imaging. Ultrasound Med Biol 2006, 32:1459-1466.
27. Ohnishi K., Chin N., Saito M., Tanaka H., Terabayashi H., Nakayama T., Iida S., Nomura F., Okuda K. Portographic opacification of hepatic veins and (anomalous) anastomoses between the portal and hepatic veins in cirrhosis-Indication of extensive intrahepatic shunts. Am J Gastroenterol 1986, 81:975-978.
28. Palacios Perez A., Salmeron Escobar J. Role of liver biopsy in the diagnosis and management of chronic hepatitis C. Gastroenterol Hepatol 2007, 30:402-407.
29. Pedersen J.F., Larsen V.A., Bytzer P., Madsen L.G., Hamberg O. Hepatic transit time of ultrasound contrast in biopsy characterized liver disease. Acta Radiol 2005, 46:557-560.
30. Phillips P., Gardner E. Contrast-agent detection and quantification. Eur Radiol 2004, 14:P4-P10.
31. Piccinino F., Sagnelli E., Pasquale G., Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986, 2:165-173.
32. Pinzani M., Vizzutti F. Fibrosis and cirrhosis reversibility: Clinical features and implications. Clin Liver Dis 2008, 12:901-913.
33. Postert T., Hoppe P., Federlein J., Helbeck S., Ermert H., Przuntek H., Buttner T., Wilkening W. Contrast agent specific imaging modes for the ultrasonic assessment of parenchymal cerebral echo contrast enhancement. J Cerebr Blood F Met 2000, 20:1709-1716.
34. Pugh R.N.H., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., Williams R. Transection of esophagus for bleeding esophageal varices. Br J Surg 1973, 60:646-649.
35. Regev A., Berho M., Jeffers L.J., Milikowski C., Molina E.G., Pyrsopoulos N.T., Feng Z.Z., Reddy K.R., Schiff E.R. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
36. Ridolfi F., Abbattista T., Marini F., Vedovelli A., Quagliarini P., Busilacchi P., Brunelli E. Contrast-enhanced ultrasound to evaluate the severity of chronic hepatitis C. Dig Liver Dis 2007, 39:929-935.
37. Rockey D. The cellular pathogenesis of portal hypertension: Stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997, 25:2-5.
38. Rockey D.C., Weisiger R.A. Endothelin-induced contractility of stellate cells from normal and cirrhotic rat liver: Implications for regulation of portal pressure and resistance. Hepatology 1996, 24:233-240.
39. Rozario R., Ramakrishna B. Histopathological study of chronic hepatitis B and C: A comparison of two scoring systems. J Hepatol 2003, 38:223-229.
40. Rubbia-Brandt L., Fabris P., Paganin S., Leandro G., Male P.J., Giostra E., Carlotto A., Bozzola L., Smedile A., Negro F. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004, 53:406-412.
41. Saadeh S., Cammell G., Carey W.D., Younossi Z., Barnes D., Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001, 33:196-200.
42. Scheuer P.J. Classification of chronic viral-hepatitis-A need for reassessment. J Hepatol 1991, 13:372-374.
43. Scheuer P.J. The nomenclature of chronic hepatitis-Time for a change. J Hepatol 1995, 22:112-114.
44. Searle J., Mendelson R., Zelesco M., Sanford J., Cheng W., McKinstry C., Ramsay D. Non-invasive prediction of the degree of liver fibrosis in patients with hepatitis C using an ultrasound contrast agent. A pilot study. J Med Imaging Radiat Oncol 2008, 52:130-133.
45. Serpaggi J., Carnot F., Nalpas B., Canioni D., Guechot J., Lebray P., Vallet-Pichard A., Fontaine H., Bedossa P., Pot S. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006, 37:1519-1526.
46. Sheth S.G., Flamm S.L., Gordon F.D., Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998, 93:44-48.
47. Staub F., Tournoux-Facon C., Roumy J., Chaigneau C., Morichaut-Beauchant M., Levillain P., Prevost C., Aubé C., Lebigot J., Oberti F., Galtier J.B., Laumonier H., Trillaud H., Bernard P.H., Blanc J.F., Sironneau S., Machet F., Drouillard J., de Ledinghen V., Couzigou P., Foucher P., Castéra L., Tranquard F., Bacq Y., d'Altéroche L., Ingrand P., Tasu J.P. Liver fibrosis staging with contrast-enhanced ultrasonography: Prospective multicenter study compared with METAVIR scoring. Eur Radiol 2009, 19:1991-1997.
48. Stieger S.M., Dayton P.A., Borden M.A., Caskey C.F., Griffey S.M., Wisner E.R., Ferrara K.W. Imaging of angiogenesis using Cadence (TM) contrast pulse sequencing and targeted contrast agents. Contrast Media Mol Imaging 2008, 3:9-18.
49. Sugimoto H., Kaneko T., Hirota M., Tezel E., Nakao A. Earlier hepatic vein transit-time measured by contrast ultrasonography reflects intrahepatic hemodynamic changes accompanying cirrhosis. J Hepatol 2002, 37:578-583.
50. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., Lok A.S.F. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
51. Wilkening W, Helbeck S, Postert T, Federlein J, Rose J, Hoppe P, Buttner T, Ermert H. Brain perfusion imaging using contrast agent specific imaging modes. 1999 IEEE Ultrasonics Symposium Proceedings, Vols. 1 and 2 1999: 1721-1724.
52. Wilkening W, Postert T, Federlein J, Kono Y, Mattrey R, Ermert H. Ultrasonic assessment of perfusion conditions in the brain and in the liver. 2000 IEEE Ultrasonics Symposium Proceedings, Vols. 1 and 2 2000: 1545-1548.
53. Yanagisawa K., Moriyasu F., Miyahara T., Yuki M., Iijima H. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 2007, 33:318-325.